Skip to Content
Morningstar

First Trust NYSE Arca Biotech ETF FBT

Morningstar Medalist Rating
Medalist Rating as of | See First Trust Investment Hub

Morningstar’s Analysis FBT

Will FBT outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable FBT’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the FBT management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of FBT’s parent organization’s priorities and whether they’re in line with investors’ interests.

The combination of an Average People Pillar rating and a Below Average Process Pillar rating limit First Trust NYSE Arca Biotech ETF to a Morningstar Medalist Rating of Negative.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBT

More FBT Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 34.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Intra-Cellular Therapies Inc

3.73 41.3 Mil
Healthcare

Exelixis Inc

3.49 38.6 Mil
Healthcare

Moderna Inc

3.48 38.5 Mil
Healthcare

Neurocrine Biosciences Inc

3.46 38.4 Mil
Healthcare

Amgen Inc

3.43 38.0 Mil
Healthcare

BeiGene Ltd ADR

3.42 37.9 Mil
Healthcare

Biogen Inc

3.42 37.9 Mil
Healthcare

United Therapeutics Corp

3.42 37.9 Mil
Healthcare

BioNTech SE ADR

3.42 37.9 Mil
Healthcare

Halozyme Therapeutics Inc

3.40 37.7 Mil
Healthcare